Loading...

Joydeep Mukherjee, PhD

TitleAssociate Researcher
InstitutionUniversity of California San Francisco
DepartmentNeurological Surgery
Address1450 3rd Street
San Francisco CA 94158
Phone415-502-7126
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Wood MD, Mukherjee J, Pieper RO. Neurofibromin knockdown in glioma cell lines is associated with changes in cytokine and chemokine secretion in vitro. Sci Rep. 2018 Apr 11; 8(1):5805. PMID: 29643433.
      View in: PubMed
    2. Mukherjee J, Johannessen TA, Ohba S, Chow TT, Jones LE, Pandita A, Pieper RO. Mutant IDH1 cooperates with ATRX loss to drive the alternative lengthening of telomere (ALT) phenotype in glioma. Cancer Res. 2018 Mar 15. PMID: 29545335.
      View in: PubMed
    3. Mahansaria R, Dhara A, Saha A, Haldar S, Mukherjee J. Production enhancement and characterization of the polyhydroxyalkanoate produced by Natrinema ajinwuensis (as synonym) = Natrinema altunense strain RM-G10. Int J Biol Macromol. 2018 Feb; 107(Pt B):1480-1490. PMID: 28987801.
      View in: PubMed
    4. Mukherjee J, Chakraborty DP, Guha G, Bose B, Saha SP. Recent Drug Resistant Epilepsy Spectrum in Eastern India. J Epilepsy Res. 2017 Jun; 7(1):39-44. PMID: 28775954.
      View in: PubMed
    5. Ohba S, Mukherjee J, Johannessen TC, Mancini A, Chow TT, Wood M, Jones L, Mazor T, Marshall RE, Viswanath P, Walsh KM, Perry A, Bell RJ, Phillips JJ, Costello JF, Ronen SM, Pieper RO. Mutant IDH1 Expression Drives TERT Promoter Reactivation as Part of the Cellular Transformation Process. Cancer Res. 2016 11 15; 76(22):6680-6689. PMID: 27758882.
      View in: PubMed
    6. Mukherjee J, Ohba S, See WL, Phillips JJ, Molinaro AM, Pieper RO. PKM2 uses control of HuR localization to regulate p27 and cell cycle progression in human glioblastoma cells. Int J Cancer. 2016 Jul 01; 139(1):99-111. PMID: 26874904.
      View in: PubMed
    7. Park I, Mukherjee J, Ito M, Chaumeil MM, Jalbert LE, Gaensler K, Ronen SM, Nelson SJ, Pieper RO. Changes in pyruvate metabolism detected by magnetic resonance imaging are linked to DNA damage and serve as a sensor of temozolomide response in glioblastoma cells. Cancer Res. 2014 Dec 01; 74(23):7115-24. PMID: 25320009; PMCID: PMC4253720.
      View in: PubMed, PubMed Central
    8. Ohba S, Mukherjee J, See WL, Pieper RO. Mutant IDH1-driven cellular transformation increases RAD51-mediated homologous recombination and temozolomide resistance. Cancer Res. 2014 Sep 01; 74(17):4836-44. PMID: 25035396; PMCID: PMC4154998.
      View in: PubMed, PubMed Central
    9. DeSouza LV, Matta A, Karim Z, Mukherjee J, Wang XS, Krakovska O, Zadeh G, Guha A, Siu KM. Role of moesin in hyaluronan induced cell migration in glioblastoma multiforme. Mol Cancer. 2013 Jul 15; 12:74. PMID: 23855374; PMCID: PMC3718631.
      View in: PubMed, PubMed Central
    10. Ito M, Ohba S, Gaensler K, Ronen SM, Mukherjee J, Pieper RO. Early Chk1 phosphorylation is driven by temozolomide-induced, DNA double strand break- and mismatch repair-independent DNA damage. PLoS One. 2013; 8(5):e62351. PMID: 23667469; PMCID: PMC3646831.
      View in: PubMed, PubMed Central
    11. Mukherjee J, Phillips JJ, Zheng S, Wiencke J, Ronen SM, Pieper RO. Pyruvate kinase M2 expression, but not pyruvate kinase activity, is up-regulated in a grade-specific manner in human glioma. PLoS One. 2013; 8(2):e57610. PMID: 23451252; PMCID: PMC3581484.
      View in: PubMed, PubMed Central
    12. Park I, Hu S, Bok R, Ozawa T, Ito M, Mukherjee J, Phillips JJ, James CD, Pieper RO, Ronen SM, Vigneron DB, Nelson SJ. Evaluation of heterogeneous metabolic profile in an orthotopic human glioblastoma xenograft model using compressed sensing hyperpolarized 3D 13C magnetic resonance spectroscopic imaging. Magn Reson Med. 2013 Jul; 70(1):33-9. PMID: 22851374; PMCID: PMC3630274.
      View in: PubMed, PubMed Central
    13. See WL, Tan IL, Mukherjee J, Nicolaides T, Pieper RO. Sensitivity of glioblastomas to clinically available MEK inhibitors is defined by neurofibromin 1 deficiency. Cancer Res. 2012 Jul 01; 72(13):3350-9. PMID: 22573716; PMCID: PMC4128256.
      View in: PubMed, PubMed Central
    14. Basu K, Mukherjee J, Law S, Chaudhuri S. Biological response modifiers influence structure function relationship of hematopoietic stem and stromal cells in a mouse model of leukemia. Asian Pac J Cancer Prev. 2012; 13(6):2935-41. PMID: 22938486.
      View in: PubMed
    15. Pramanik A, Sundararaman M, Das S, Ghosh U, Mukherjee J. ISOLATION AND CHARACTERIZATION OF CYANOBACTERIA POSSESSING ANTIMICROBIAL ACTIVITY FROM THE SUNDARBANS, THE WORLD'S LARGEST TIDAL MANGROVE FOREST(1). J Phycol. 2011 Aug; 47(4):731-43. PMID: 27020009.
      View in: PubMed
    16. McLarty K, Moran MD, Scollard DA, Chan C, Sabha N, Mukherjee J, Guha A, McLaurin J, Nitz M, Houle S, Wilson AA, Reilly RM, Vasdev N. Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice. Nucl Med Biol. 2011 Oct; 38(7):953-9. PMID: 21982567.
      View in: PubMed
    17. Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, Hawkins C, Guha A. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med. 2011 Feb 14; 208(2):313-26. PMID: 21242296; PMCID: PMC3039857.
      View in: PubMed, PubMed Central
    18. Bhola P, Banerjee S, Mukherjee J, Balasubramanium A, Arun V, Karim Z, Burrell K, Croul S, Gutmann DH, Guha A. Preclinical in vivo evaluation of rapamycin in human malignant peripheral nerve sheath explant xenograft. Int J Cancer. 2010 Jan 15; 126(2):563-71. PMID: 19634141.
      View in: PubMed
    19. Mukherjee J, DeSouza LV, Micallef J, Karim Z, Croul S, Siu KW, Guha A. Loss of collapsin response mediator Protein1, as detected by iTRAQ analysis, promotes invasion of human gliomas expressing mutant EGFRvIII. Cancer Res. 2009 Nov 15; 69(22):8545-54. PMID: 19903856.
      View in: PubMed
    20. Micallef J, Taccone M, Mukherjee J, Croul S, Busby J, Moran MF, Guha A. Epidermal growth factor receptor variant III-induced glioma invasion is mediated through myristoylated alanine-rich protein kinase C substrate overexpression. Cancer Res. 2009 Oct 01; 69(19):7548-56. PMID: 19773446.
      View in: PubMed
    21. Mukherjee J, Kamnasaran D, Balasubramaniam A, Radovanovic I, Zadeh G, Kiehl TR, Guha A. Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate). Cancer Res. 2009 Jun 15; 69(12):5099-107. PMID: 19509233.
      View in: PubMed
    22. Harris MA, Yang H, Low BE, Mukherjee J, Mukherje J, Guha A, Bronson RT, Shultz LD, Israel MA, Yun K. Cancer stem cells are enriched in the side population cells in a mouse model of glioma. Cancer Res. 2008 Dec 15; 68(24):10051-9. PMID: 19074870; PMCID: PMC2841432.
      View in: PubMed, PubMed Central
    23. Ghosh A, Mukherjee J, Bhattacharjee M, Sarkar P, Acharya S, Chaudhuri S, Chaudhuri S. The other side of the coin: beneficiary effect of 'oxidative burst' upsurge with T11TS facilitates the elimination of glioma cells. Cell Mol Biol (Noisy-le-grand). 2007 May 30; 53(5):53-62. PMID: 17543233.
      View in: PubMed
    24. Bhattacharjee M, Bose I, Sarkar P, Banerjee C, Dutta S, Ghosh A, Mukherjee J, Acharya S, Goswami S, Mazumdar A, Chaudhuri S, Chaudhuri S. A sequential scanning of the immune efficiency in astrocytoma (Grade I to Grade Iii), meningioma and secondary glioma patients with and without therapeutic scheduling. Cancer Invest. 2006 Aug-Sep; 24(5):502-13. PMID: 16939959.
      View in: PubMed
    25. Mukherjee J, Ghosh A, Ghosh A, Chaudhuri S. ENU administration causes genomic instability along with single nucleotide polymorphisms in p53 during gliomagenesis: T11TS administration demonstrated in vivo apoptosis of these genetically altered tumor cells. Cancer Biol Ther. 2006 Feb; 5(2):156-64. PMID: 16357521.
      View in: PubMed
    26. Mukherjee J, Ghosh A, Sarkar P, Mazumdar M, Banerjee C, Chaudhuri S. Immunotherapy with T11TS / S-LFA-3 specifically induces apoptosis of brain tumor cells by augmenting intracranial immune status. Anticancer Res. 2005 Jul-Aug; 25(4):2905-19. PMID: 16080544.
      View in: PubMed
    27. Mukherjee J, Ghosh A, Sarkar S, Mazumdar M, Sarkar P, Duttagupta AK, Chaudhuri S. T11TS/S-LFA3 induces apoptosis of the brain tumor cells: a new approach to characterise the apoptosis associated genetic changes by arbitrarily primed-PCR. Cancer Lett. 2005 May 10; 222(1):23-38. PMID: 15837538.
      View in: PubMed
    28. Sarkar S, Ghosh A, Dutta S, Roy RU, Begum Z, Mukherjee J, Chaudhuri S, Chaudhuri S. Sheep erythrocyte demonstrated better effect than IL-2 and IFN-gamma as biological response modifier against glioma in experimental model. Indian J Exp Biol. 2005 May; 43(5):414-9. PMID: 15900905.
      View in: PubMed
    29. Guha A, Mukherjee J. Advances in the biology of astrocytomas. Curr Opin Neurol. 2004 Dec; 17(6):655-62. PMID: 15542973.
      View in: PubMed
    30. Sarkar S, Ghosh A, Mukherjee J, Chaudhuri S, Chaudhuri S. CD2-SLFA3/T11TS interaction facilitates immune activation and glioma regression by apoptosis. Cancer Biol Ther. 2004 Nov; 3(11):1121-8. PMID: 15467439.
      View in: PubMed
    31. Ghosh A, Sarkar S, Begum Z, Dutta S, Mukherjee J, Bhattacharjee M, Sarkar P, Banerjee C, Mandal M, Mazumdar A, Bhattacharjee MK, Chaudhuri S, Chaudhuri S. The first cross sectional survey on intracranial malignancy in Kolkata, India: reflection of the state of the art in southern West Bengal. Asian Pac J Cancer Prev. 2004 Jul-Sep; 5(3):259-67. PMID: 15373704.
      View in: PubMed
    32. Mukherjee J, Sarkar S, Ghosh A, Duttagupta AK, Chaudhuri S, Chaudhuri S. Immunotherapeutic effects of T11TS/S-LFA3 against nitrosocompound mediated neural genotoxicity. Toxicol Lett. 2004 May 02; 150(3):239-57. PMID: 15110076.
      View in: PubMed
    33. Begum Z, Ghosh A, Sarkar S, Mukherjee J, Mazumdar M, Sarkar P, Chaudhuri S. Documentation of immune profile of microglia through cell surface marker study in glioma model primed by a novel cell surface glycopeptide T11TS/SLFA-3. Glycoconj J. 2004; 20(9):515-23. PMID: 15454689.
      View in: PubMed
    34. Sarkar P, Mukherjee J, Ghosh A, Bhattacharjee M, Mahato S, Chakraborty A, Mondal M, Banerjee C, Chaudhuri S. A comparative analysis of immunorestoration and recovery with conventional and immunotherapeutic protocols in canine generalized demodicosis: a newer insight of immunotherapeutic efficacy of T11TS. Immunol Invest. 2004; 33(4):453-68. PMID: 15624702.
      View in: PubMed
    35. Begum Z, Sarkar S, Mukherjee J, Ghosh A, Chaudhuri S, Chaudhuri S. Evaluation of anti-tumor property of specific and non-specific BRMs in experimental gioma by assessing the microglial cell functional and phenotypic modulations. Cancer Biol Ther. 2003 Jul-Aug; 2(4):356-63. PMID: 14508105.
      View in: PubMed
    36. Mukherjee J, Dutta S, Sarkar S, Begum Z, Ghosh A, Chaudhuri S, Chaudhuri S. Preclinical Changes in Immunoreactivity and Cellular Architecture during the Progressive Development of Intracranial Neoplasms and an Immunotherapeutic Schedule with a Novel Biological Response Modifier, the T11TS / S-LFA3. Asian Pac J Cancer Prev. 2002; 3(4):325-337. PMID: 12716291.
      View in: PubMed
    Joydeep's Networks
    Concepts
    Derived automatically from this person's publications.
    See all (235) concept(s)
    _
    Co-Authors
    People in Profiles who have published with this person.
    See all (17) people
    _
    Related Authors
    People who share related concepts with this person.
    See all (60) people
    _
    ↑